Compare BCAB & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCAB | SRBK |
|---|---|---|
| Founded | 2007 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 140.5M |
| IPO Year | 2020 | 2023 |
| Metric | BCAB | SRBK |
|---|---|---|
| Price | $4.20 | $19.86 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 51.5K | 40.7K |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.04% |
| EPS Growth | 29.86 | ★ 138.36 |
| EPS | N/A | ★ 0.31 |
| Revenue | ★ $300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $63.32 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $13.47 |
| 52 Week High | $6.52 | $20.20 |
| Indicator | BCAB | SRBK |
|---|---|---|
| Relative Strength Index (RSI) | 59.93 | 62.21 |
| Support Level | $3.92 | $18.51 |
| Resistance Level | $4.22 | N/A |
| Average True Range (ATR) | 0.39 | 0.43 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 88.54 | 63.43 |
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.